DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,357,723 B2 Satyam (45) Date of Patent: Jan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US008357723B2 (12) United States Patent (10) Patent No.: US 8,357,723 B2 Satyam (45) Date of Patent: Jan. 22, 2013 (54) PRODRUGS CONTAINING NOVEL "Nitric Oxide Donors and Cardiovascular Agents Modulating the BO-CLEAVABLE LINKERS Bioactivity of Nitric Oxide: An Overview” by Louis J. Ignarro, et al., Circulation Research, vol. 90, No. 1, pp. 21-22 (Jan. 11, 002). (75) Inventor: Apparao Satyam, Mumbai (IN) “Bis3-(4-substituted phenyl)prop-2-enedisulfides as a new class of (73) Assignee: Piramal Enterprises Limited and antihyperlipidemic compounds' by Meenakshi Sharma, et al., Apparao Satyam, Mumbai (IN) Bioorganic and Medicinal Chemistry Leters, vol. 14, No. 21, pp. (*) Notice: Subject to any disclaimer, the term of this 5347-5350 (Nov. 1, 2004). patent is extended or adjusted under 35 Abstract Only "Spectrophotometric determination of binary mix U.S.C. 154(b) by 0 days. tures of pseudoephedrine with some histamine H1-receptor antago nists using derivative radio spectrum method' by H. Mahgouh, et al., (21) Appl. No.: 12/977,929 J. Pham Biomed Anal, vol. 31, No. 4, pp. 801-809 Mar. 26, 2003. (22) Filed: Dec. 23, 2010 Peter D. Senter et al., Development of Drug-Release Strategy Based (65) Prior Publication Data on the Reductive Fragmentation pf Benzyl Carbamate Disulfides. Journal of Organic Chemistry, 1990, 55, 2975-2978. Published by US 2011 FO269709 A1 Nov. 3, 2011 American Chemical Society (USA). Related U.S. Application Data Vivekananda M. Virudhula et al., Reductively Activated Disulfide Prodrugs of Paclitaxel. Biorganic & Medicinal Chemistry Letters, (62) Division of application No. 1 1/213,396, filed on Aug. 2002, 12, 3591-35-94, Published by Elsvier Sciences LTD. (USA). 26, 2005, now Pat. No. 7,932,294. Samuel Zalipsky et al., New Detachable Poly(ethylene glycol) Con jugates: Cysteinecleavable Lipopolymers Regenerating Natural (60) Provisional application No. 60/604,632, filed on Aug. Phospholipid, Diacyl Phosphatidylethanolamine. Bioconiugate 26, 2004. Chemistry, Published by American Chemical Society (USA). 1999, (30) Foreign Application Priority Data vol. 10, No. 5, pp. 703-707. Kexin Yang et al., Synthesis of novel organic nitrate esters: guanylate Jan. 7, 2005 (IN) ........................... 779/MUM/2005 cyclase activation and tissue relaxation. Journal of Chemical Society, Perkin Transitions 1, 1996, 1073-1075, Publised by Royal Society of (51) Int. Cl. Chemistry (UK). A6 IK3I/O5 (2006.01) Sergei I. Zavorin et al., Nitrate Esters as Nitric Oxide Donors: SS C07C323/2 (2006.01) Nitrates. Organic Letters, 2001.3 (8), 1113-1116. Published by (52) U.S. Cl. .......................................... 514/707:568/22 American Chemical Society (USA). Abstract, Zhdanovich, E.S., et al. Zhumal Obshchei Khimi (1967), (58) Field of Classification Search .................. 514/707; 37(2), 361-3. 568/22 Abstract, Oiry, Joel, et al. “Centre National de la Recherche See application file for complete search history. Scientifique, Fr.” Fr. Demande (1983) (FR 2528042). Abstract, Joel, et al. “Centre National de la Recherche Scientifique, (56) References Cited Fr” Eur, Patent Applin. 131500 (1885) 64 pp. Abstract, Barcelo, Gerard, et al. (Soceite Nationale des Pourdes et U.S. PATENT DOCUMENTS Explosifs, Fr. Fr. Demande (1987), FR 25898.60. 5,767,134 A 6, 1998 Li et al. Abstract, Davidovich, Yu, et al. Izvestiya Akademii Nauk SSSR, 5,807,847 A 9, 1998 Thatcher et al. Seriya Khimicheskaya (1989), (8), 1918-20. 5,883,122 A 3, 1999 Thatcher et al. Abstract, Vecsei, Laszlo, et al. Progress in Neuro-Psychopharmacol 6,369,071 B1 4/2002 Haj-Yehia ogy & Biological Psychiatry (1990), 14(6),835-62. 6,566,509 B1 5, 2003 Griffin et al. Abstract, Guetschow, Michael, et al. DD 293807 (Ger. (East)) (1991). 2003/0044845 A1 3/2003 Jenkins et al. Abstract, Oiry, J. et al. European Journal of Medicinal Chemistry 2004/O147598 A1 7/2004 Haj-Yehia (1992), 27(8), 809-17. 2005.0002942 A1 1/2005 Vlahov et al. Abstract, Thoene, Jess G. et al. WO9306832 1993. FOREIGN PATENT DOCUMENTS Smith et al. “Urethans of 2-Mercaptoethanol” Journal of the Ameri can Chemical Society, 1959, vol. 81, pp. 161-163. EP O317956 5, 1989 WO 97,46521 12/1997 WO 98.42661 10, 1998 * cited by examiner WO 99.58152 11, 1999 WO OO,54756 9, 2000 Primary Examiner — Joseph Kosack WO OO64483 11, 2000 (74) Attorney, Agent, or Firm — Ladas & Parry LLP WO O1? 13957 3, 2001 WO O1/49275 A2 T 2001 (57) ABSTRACT WO O3,000643 A1 1, 2003 WO 03/040 104 5, 2003 The invention provides the compounds of formula (I) or phar WO 2004/004648 A2 1, 2004 maceutically acceptable salts thereof. The invention also pro WO 2004/O12659 A2 2, 2004 WO 2004/O39771 5, 2004 vides pharmaceutical compositions comprising one or more WO 2004/0691.59 8, 2004 compounds of formula I or intermediates thereof and one WO 2004f1 10432 A1 12/2004 more of pharmaceutically acceptable carriers, vehicles or WO 2005/030 135 A2 4/2005 diluents. The invention further provides methods of prepara tion and methods of use of prodrugs including NO-releasing OTHER PUBLICATIONS prodrugs, double prodrugs and mutual prodrugs comprising Lartia et al. “New reagent for the preparation of oligonucleotides the compounds of formula I. involving a 5'-thiophosphate or a 5'-phosphate group” Tetrahedron Letters, 2004, pp. 5949-5952.* 16 Claims, 1 Drawing Sheet U.S. Patent Jan. 22, 2013 US 8,357,723 B2 ru-Aspirin -v--C1-NOPO4 ada -C1-NOPOSA on 1-C1-NOPD5B US 8,357,723 B2 1. 2 PRODRUGS CONTAINING NOVEL Prize in Medicine and Physiology. NO is a major signaling BO-CLEAVABLE LINKERS molecule with important biological roles. See, for example, Kerwin, Jr., J. F. et al., J. Med. Chem. 1995, 38, 4343, and This is a divisional of application Ser. No. 1 1/213,396 filed Williams. R. J. P. Chem. Soc. Rev., 1996, 77. The major on Aug. 26, 2005, now U.S. Pat. No. 7,932.294 claims the 5 biological functions of NO include controlling blood pres benefit thereof and incorporates the same by reference. Sure, Smoothing muscle tone and inhibition of platelet adher This application takes priority from US Provisional Appli ence and aggregation, assisting the immune system in cation Ser. No. 60/604,632 filed 26 Aug. 2004 and Indian destroying tumor cells and intracellular pathogens and par Provisional Application 779/MUM/2005 filed 1 Jul. 2005, ticipating in neuronal synaptic transmission. See, for which are herein incorporated in their entirety. 10 example, Moncada, S. et al., Pharmacol. Rev. 1991, 43, 109: Bredt, D. S. et al., Anuu. Rev. Biochem., 1994, 63, 175; FIELD OF THE INVENTION Schmidt, H. H. W. et al., Cell 1994, 78,919: Feldman, P. L. et al., Chem. and Eng. News. 1993, 71 (20th December issue), The present invention relates to compositions of prodrugs, 26; and Wilsonm E. K., Chem. and Eng. News. 2004 (8' including NO-releasing prodrugs, codrugs, double prodrugs 15 March issue), 39. Endogenously, NO is produced from argi and mutual prodrugs, containing bio-labile linkers and link nine by the catalytic action of nitric oxide synthase. See, for ages, processes for their preparation and pharmaceutical example, Nathan, C. et al., Cell 1994, 78,915, and Marietta, compositions containing them and their use. M.A., Cell 1994, 78,927. NO is a free radical as well as a scavenger of free radicals. BACKGROUND OF THE INVENTION NO reacts quickly with ubiquitously generated reactive oxy gen species (ROS) such as Superoxide (O) to generate a A prodrug is an active drug chemically transformed into a nefarious peroxynitrite (ONOOT) molecule, which is impli per se inactive derivative which by virtue of chemical or cated in many human diseases such as diabetes, heart disease, enzymatic attack is converted to the parent drug within the Alzheimer's disease and multiple Sclerosis. In this setting, body before or after reaching the site of action. The process of 25 NO is often viewed as pathogenic. However, the chemistry of converting an active drug into inactive form is called drug NO can also be a significant factor in lessening the injury latentiation. Prodrugs can be carrier-linked-prodrugs and bio mediated by reactive oxygen species (ROS) and reactive precursors. The carrier-linked prodrug results from a tempo nitrogen oxide species (RNOS). There is a relationship rary linkage of the active molecule with a transport moiety. between NO and oxidation, nitrosation and nitration reac Such prodrugs are less active or inactive compared to the 30 tions. A number of factors determine whether NO promotes, parent active drug. The transport moiety will be chosen for its abates or interconnects these chemistries. See, for example, non-toxicity and its ability to ensure the release of the active Espay, et al. A chemical perspective on the interplay between principle with efficient kinetics. Whereas the bioprecursors NO, reactive oxygen species, and reactive nitrogen oxide result from a molecular modification of the active principle species, Ann N.Y. Acad. Sci. 2002, 962, 195. itself by generation of a new molecule that is capable of being 35 Thus, by being a free radical, along with the ability to a Substrate to the metabolizing enzymes releasing the active Scavenge other free radicals, NO is placed in a pivotal regu principle as a metabolite. latory position. Insight into these pathophysiological pro Prodrugs are prepared to alter the drug pharmacokinetics, cesses and signaling are highly relevant to develop therapeu improve stability and solubility, decrease toxicity, increase tics. specificity, and increase duration of the pharmacological 40 NO deficiency has been implicated in the genesis and evo effect of the drug. By altering pharmacokinetics the drug lution of several disease states. In patients with cardiovascu bioavailability is increased by increasing absorption, distri lar problems, the production of Superoxide is increased and bution, biotransformation, and excretion of the drug.
Recommended publications
  • 1-(4-Amino-Cyclohexyl)

    1-(4-Amino-Cyclohexyl)

    (19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art.
  • Stems for Nonproprietary Drug Names

    Stems for Nonproprietary Drug Names

    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
  • Basic Pharmacology

    Basic Pharmacology

    Name ___________________________________________ Date _________ Score _________ CHAPTER 35 Basic Pharmacology CHAPTER PRE-TEST Perform this test without looking at your book. 1. The Physician’s Desk Reference contains which of the following information? a. Brand and generic names of medications b. Classification or category c. Product information d. All of the above 2. An agent that produces numbness is called an: a. Analgesic b. Anesthetic c. Anticoagulant d. Antidote 3. Ibuprofen is considered which classification of medications? a. Sedative b. Nonsteroidal anti-inflammatory c. Vasopressor d. Decongestant 4. A liquid preparation of a drug is one that has been: a. Dissolved b. Suspended c. Crushed d. a and b 5. Misuse or overuse of medications is termed: a. Medication error b. Diversion c. Abuse d. All of the above 369 03047_sg_ch35_ptg01_hr_369_380.indd 369 DESIGN SERVICES OF 30/05/13 3:03 PM # 110592 Cust: Cengage Au: Lindh Pg. No. 369 K S4-CARLISLE Title: Study Guide to accompany Delmar’s Comprehensive Medical Assisting: Server: Short / Normal / Long Publishing Services 370 Chapter 35 • Chapter Assignment Sheets 6. Hydromorphone, oxycodone, and morphine are Schedule drugs. a. I b. II c. III d. IV 7. A drug’s official name assigned by the U.S. Adopted Names Council is: a. The generic name b. The brand name c. The chemical name d. All of the above 8. Which of the following are the responsibilities of the medical assistant as they relate to controlled substances? a. Provide security for prescription pads b. Properly dispose of and document the disposal of expired drugs c. Maintain legal inventories of medications d.
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • CNS Spectrums

    CNS Spectrums

    CNS Spectrums http://journals.cambridge.org/CNS Additional services for CNS Spectrums: Email alerts: Click here Subscriptions: Click here Commercial reprints: Click here Terms of use : Click here The following abstracts were presented as posters at the 2015 NEI Psychopharmacology Congress CNS Spectrums / Volume 21 / Issue 01 / February 2016, pp 77 - 121 DOI: 10.1017/S1092852915000905, Published online: 22 February 2016 Link to this article: http://journals.cambridge.org/abstract_S1092852915000905 How to cite this article: (2016). The following abstracts were presented as posters at the 2015 NEI Psychopharmacology Congress. CNS Spectrums, 21, pp 77-121 doi:10.1017/S1092852915000905 Request Permissions : Click here Downloaded from http://journals.cambridge.org/CNS, IP address: 12.12.207.2 on 15 Mar 2016 CNS Spectrums (2016), 21,77–121. © Cambridge University Press 2016 doi:10.1017/S1092852915000905 ABSTRACTS The following abstracts were presented as posters at the 2015 NEI Psychopharmacology Congress Congratulations to the scientific poster winners of the 2015 NEI Psychopharmacology Congress! st 1 PLACE: Tardive Dyskinesia in the Era of Second Generation Antipsychotics: A Case Report and Literature Review (page 22) nd 2 PLACE: Comparing Deep Brain Stimulation (DBS) and ECT for Treatment Resistant Depression in Elderly Population (page 37) rd 3 PLACE: The Complex Multimodal Management of First-Psychotic Episode in Patients with Morphometric Alteration in Hippocampal Formation (page 30) Violent Video Games – Physiological and variability, emotion, sleep quality, violent video game, Psychological Impact on Children and desensitization, aggressiveness”. Adolescents: Literature Review RESULTS: Literature so far shows an association between Sree Latha Krishna Jadapalle, MD1 and Monifa daily exposure to violent video games and number of Seawell, MD1 depressive and anxiety symptoms among pre-adolescent youth.
  • Antiepileptic Drugs: Evolution of Our Knowledge and Changes in Drug Trials

    Antiepileptic Drugs: Evolution of Our Knowledge and Changes in Drug Trials

    ILAE 110th anniversary review paper* Epileptic Disord 2019; 21 (4): 319-29 Antiepileptic drugs: evolution of our knowledge and changes in drug trials Emilio Perucca Past President of the International League Against Epilepsy Division of Clinical and Experimental Pharmacology, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia and IRCCS Mondino Foundation, Pavia, Italy Received April 30, 2019; Accepted June 01, 2019 ABSTRACT – Clinical trials provide the evidence needed for rational use of medicines. The evolution of drug trials follows largely the evolution of regulatory requirements. This article summarizes methodological changes in antiepileptic drug trials and associated advances in knowledge starting from 1938, the year phenytoin was introduced and also the year when evi- dence of safety was made a requirement for the marketing of medicines in the United States. The first period (1938-1969) saw the introduction of over 20 new drugs for epilepsy, many of which did not withstand the test of time. Only few well controlled trials were completed in that period and trial designs were generally suboptimal due to methodological constraints. The intermediate period (1970-1988) did not see the introduction of any major new medication, but important therapeutic advances took place due to improved understanding of the properties of available drugs. The value of therapeutic drug monitoring and monotherapy were recognized dur- ing the intermediate period, which also saw major improvements in trial methodology. The last period (1989-2019) was dominated by the introduc- tion of second-generation drugs, and further evolution in the design of monotherapy and adjunctive-therapy trials. The expansion of the pharma- cological armamentarium has improved opportunities for tailoring drug treatment to the characteristics of the individual.
  • P=.004), Comparable. Median Post-LT VPA-ALF Contraindicated for Acute

    P=.004), Comparable. Median Post-LT VPA-ALF Contraindicated for Acute

    and 76% were due to neurocysticercosis. (Arya R, Gulati S, Kabra M, Sahu JK, Kalra V. Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children. Neurology April 12, 2011;76:1338-1343). (Response and reprints: Dr Sheffali Gulati, Department of Pediatrics, AIIMS, Ansari Nagar, New Delhi, 110 029, India. E-mail: [email protected] COMMENT. Gingival hyperplasia associated with phenytoin treatment of epilepsy is reported in as few as 3% of cases (Lennox WG, 1940) to as many as 78% (Gardner AF et al, 1962). It occurs more frequently in children than in adults. Numerous mechanisms have been proposed but few of proven significance. Other hydantoin anticonvulsants (mephenytoin, ethotoin, and albutoin) cause little or no gingival hyperplasia. The above investigators have discovered an important and correctable factor in the mechanism in their clinic population. The authors allude to a lack of dental hygiene in a high proportion of patients, a known contributing factor associated with tissue inflammation and irritation. Hyperplasia does not occur in edentulous adults. Phenytoin has an affinity for gingival tissue, and its effect on collagen and keratin in connective tissue has been used in the promotion of healing of wounds and leg ulcers (Shafer WG et al, 1958; Houck JC et al, 1972). In addition to man, only the ferret is susceptible to phenytoin gum hyperplasia, an interesting companion in science. Mechanisms largely disproven include a deficiency of ascorbic acid, adrenocortical dysfunction, and allergy (Gardner, 1962). Hyperglycemia induced by phenytoin, an effect discovered in our neurology research laboratories at Children's Memorial Hospital (Belton NR et al.
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Issue #81-92, 1976

    Issue #81-92, 1976

    ISSN 0090-1350 LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN of the Library Component of the Biomedical Communications Network No 81 January 197 THE CONTENTS OF THIS PUBLICATION ARE NOT COPYRIGHTED AND MAY BE FREELY REPRODUCED TABLE OF CONTENTS Page Journal Citation Data Bases 2 On-line Technical Notes 2 Proposed Conversion from TSO to TCAM Message Handler As NLM's Teleprocessing Interface 5 Hedges , 9 Responsible Use of On-line Data Bases 11 An Experiment in On-Site Training, Madison, Wisconsin — December 15-19, 1975 12 Tumor Key Errata 14 MEDLINE Trainees at the University of Wisconsin, December 15, 1975 14 New Serials Announcement - December 1975 15 MEDLINE Trainees at NLM, January 12, 1976 17 U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service National Institutes of Health LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN of the Library Component of the Biomedlcal Communications Network JOURNAL CITATION DATA BASES EDITOR Grace H. McCarn Head, MEDLARS Management Section MEDLINE and SDILINS were updated with National Library of Medicine February 1976 citations at NLM and SUNY on 8600 Rockville Pike January 12. The sizes, Index Medicus date Bethesda, Maryland 20014 ranges, and entry date ranges are given (301) 496-6193 TWX: 710-824-9616 below: ASSISTANT EDITOR P.E. Pothier MEDLINE (Jan 74 - Feb 76) - 486,93? (Entry Dates: 731130 to 760102) TECHNICAL NOTES EDITOR Leonard J. Bahlman SDILINE (Feb 76) - 21,138 (Entry Dates: 751210 to 761012) The LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN is issued monthly by the Office of the Associate Director for Library Operations. ON-LINE TECHNICAL NOTES PLEASE QUERY THE NLM/ON-LINE NEWS FILES DAILY FOR SPECIAL NOTICES AND MESSAGES Whenever applicable, in the margin beside each Technical Note., users will be referred to the section/page of the NLM On-Line Services Reference Manual which is considered most relevant to the item being discussed (e.g.., Manual II-9) .
  • The Evidence Base for the Classification of Drugs

    The Evidence Base for the Classification of Drugs

    THE ARTS This PDF document was made available from www.rand.org as a public CHILD POLICY service of the RAND Corporation. CIVIL JUSTICE EDUCATION Jump down to document ENERGY AND ENVIRONMENT 6 HEALTH AND HEALTH CARE INTERNATIONAL AFFAIRS The RAND Corporation is a nonprofit research NATIONAL SECURITY POPULATION AND AGING organization providing objective analysis and effective PUBLIC SAFETY solutions that address the challenges facing the public SCIENCE AND TECHNOLOGY and private sectors around the world. SUBSTANCE ABUSE TERRORISM AND HOMELAND SECURITY TRANSPORTATION AND INFRASTRUCTURE Support RAND WORKFORCE AND WORKPLACE Browse Books & Publications Make a charitable contribution For More Information Visit RAND at www.rand.org Explore RAND Europe View document details Limited Electronic Distribution Rights This document and trademark(s) contained herein are protected by law as indicated in a notice appearing later in this work. This electronic representation of RAND intellectual property is provided for non- commercial use only. Permission is required from RAND to reproduce, or reuse in another form, any of our research documents for commercial use. This product is part of the RAND Corporation technical report series. Reports may include research findings on a specific topic that is limited in scope; present discus- sions of the methodology employed in research; provide literature reviews, survey instruments, modeling exercises, guidelines for practitioners and research profes- sionals, and supporting documentation; or deliver preliminary findings. All RAND reports undergo rigorous peer review to ensure that they meet high standards for re- search quality and objectivity. The Evidence Base for the Classification of Drugs Ruth Levitt, Edward Nason, Michael Hallsworth Prepared for the UK House of Commons Committee on Science and Technology The research described in this report was prepared for the UK House of Commons Select Committee on Science and Technology.
  • Stembook 2018.Pdf

    Stembook 2018.Pdf

    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum

    A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum

    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic